Production (Stage)
Allogene Therapeutics, Inc.
ALLO
$1.06
-$0.03-2.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 8.10% | 30.12% | -6.43% | 16.25% | 34.98% |
| Total Depreciation and Amortization | -12.83% | -7.02% | -10.22% | 0.03% | 1.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.17% | -56.22% | 23.87% | -12.24% | -50.02% |
| Change in Net Operating Assets | -46.80% | 203.90% | 54.00% | -284.26% | -176.13% |
| Cash from Operations | 5.31% | 31.67% | 20.56% | -2.80% | 16.12% |
| Capital Expenditure | -1,137.50% | -41.99% | -3,475.00% | 100.00% | 99.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -71.66% | -18.41% | -120.59% | 327.63% | -80.57% |
| Cash from Investing | -72.10% | -18.57% | -121.76% | 334.81% | -80.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 544.85% | 3,605.16% | -84.15% | 18.76% | -4.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 747.88% | 3,605.16% | -84.15% | 21.31% | -4.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.01% | 72.40% | -39.66% | 166.87% | -166.87% |